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Abstract 
TRAIL is a promising candidate for cancer therapy, as it can induce apoptosis 
specifically in tumor cells but not in normal cells. While earlier mouse tumor 
studies revealed a strong tissue dependency of TRAIL and its death receptor in 
suppressing primary tumorigenesis or experimental metastases, we recently 
found that TRAIL-R inhibits lymph node metastases without affecting primary 
tumor formation in a mouse model of multistage skin tumorigenesis. This finding 
uncouples the role of TRAIL in primary tumorigenesis from metastasis formation, 
likely by sensitization of previously TRAIL-resistant tumor cells upon detachment, 
an early step required for metastasis formation. Therefore, TRAIL-R is a novel 
metastasis suppressor, suggesting that TRAIL-related tumor therapy might be 
most effective in primary tumors and early metastatic cancers, before selection 
for TRAIL resistance occurs.  
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The apoptosis-inducing TRAIL system in primary tumorigenesis and 
metastasis 
The TNF-related apoptosis inducing ligand (TRAIL/Apo2L) is a transmembrane 
protein expressed on activated cells of the immune system such as NK cells, T 
and B lymphocytes, monocytes, and dendritic cells. TRAIL binds to receptors 
containing a death domain, called death receptors. In humans, TRAIL has two 
receptors containing a death domain, TRAIL-R1 (DR4) and TRAIL-R2 
(DR5/KILLER/TRICK2/APO2), while there is only one death receptor in mice 
equally homologous to both human death receptors, called TRAIL-R (1). In 
addition, in both humans and mice TRAIL can also bind to three different 
receptors with no functional death domains, also referred to as “decoy” or 
“regulatory receptors”. However, the physiological function of these receptors 
with respect to TRAIL-signaling has not yet been fully investigated (1). Ligation of 
TRAIL death receptors can activate the extrinsic apoptosis pathway by recruiting 
the adaptor molecule FADD resulting in Caspase-8 and Caspase-3 activation (2). 
For the biopharmaceutical industry TRAIL has raised considerable interest, as 
TRAIL was shown to preferentially kill tumor cells while non-transformed cells 
remained TRAIL-resistant in vitro and in vivo. Also, at least one of the two TRAIL 
death receptors is expressed on all cancer cells examined. Therefore, targeting 
the apoptosis-inducing TRAIL system is a promising anti-tumor strategy with little 
side effects. Recombinant TRAIL or agonistic antibodies against the human 
TRAIL death receptors are currently in clinical trials. Although 30-50% of tested 
human cancer cell lines are TRAIL-resistant (3), most can be sensitized to TRAIL 
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by prior treatment with chemotherapeutics, proteasome inhibitors or  γ-irradiation 
(1).  
Due to these tumor cell-specific effects, it was suggested that a physiological role 
of the TRAIL system is tumor suppression. Indeed, transplantation of TRAIL-
sensitive tumor cells into syngeneic TRAIL-deficient mice led to increased 
subcutaneous tumor growth and experimental liver metastases (4, 5). This 
observed tumor surveillance effect of TRAIL was at least in part dependent on 
expression of TRAIL by activated liver NK cells  (4, 6). Interestingly, lung NK cells 
do not express TRAIL (6), which could explain why experimental lung 
metastases were not accelerated in TRAIL-deficient mice (5, 7) and 
demonstrates a tissue-specific effect of TRAIL-mediated tumor immune 
surveillance (6).  
Autochthonous mouse tumor models using TRAIL and TRAIL-R-deficient mice 
also revealed a strong tissue dependency of tumor suppression by TRAIL and 
TRAIL-R. In some tissues, such as liver, lymphoid tissues (8), and muscle, the 
TRAIL system can inhibit primary tumor formation, while in epithelial tissues such 
as mammary gland and colon it had no observable effect (1). Consistently, we 
found recently that neither carcinogen-induced skin tumor initiation nor tumor 
growth or conversion was accelerated in TRAIL-R-deficient mice (9). So far, the 
reason for this observed tissue dependency of the tumor suppressor function of 
the TRAIL system is unclear. Although both mammary and skin cancer cell lines 
express TRAIL-R on their surface (9, 10), it remains to be determined whether 
primary tumor cells are TRAIL-resistant in vivo and/or whether insufficient TRAIL-
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expressing killer cells of the immune system gain access to those primary 
epithelial tumors. In addition, the tumor suppressor function of the TRAIL system 
in some tissues could be dependent on non-apoptotic functions of TRAIL and 
TRAIL-R signaling; there is some evidence that TRAIL-R can have an anti-
inflammatory effect resulting in tumor protection (8).  
TRAIL-R as a metastasis suppressor    
Despite no difference in primary skin tumorigenesis in TRAIL-R-deficient mice, 
they developed a greater number of metastases to the lymph nodes than wild-
type littermates (9). This was the first demonstration that TRAIL-R signaling could 
inhibit metastasis from autochthonous tumors, and that TRAIL-R can exert its 
anti-tumor effect in a tumor stage-dependent manner. Interestingly, carcinoma 
cells isolated from primary skin tumors of wild-type mice were initially TRAIL 
resistant. Since the latency of primary skin tumors was not affected by TRAIL-R 
deficiency, we concluded that selection for TRAIL resistance of skin carcinoma 
cells during primary tumorigenesis was unlikely. An early required step in 
metastasis formation is detachment of tumor cells from the extracellular matrix. In 
epithelial cells this can lead to anoikis as well as to sensitization of cells to 
apoptosis (11). While anoikis appeared to be TRAIL-R-independent, detachment 
increased sensitivity of skin carcinoma cells to exogenously added TRAIL (9). 
Detachment-induced TRAIL sensitization has also been reported in breast 
carcinoma cells (12) and ovarian carcinoma cells (13). The sensitization of skin 
carcinoma cells to TRAIL by detachment correlated with downregulation of ERK 
activity and inhibition of ERK activity sensitized attached carcinoma cells to 
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TRAIL (9). In summary, the sensitization of carcinoma cells to TRAIL by 
detachment, provides an explanation for how the TRAIL system can suppress 
metastases without affecting primary tumor formation. Furthermore, our data 
suggest that even if the primary tumor is TRAIL resistant there could be a natural 
window of TRAIL sensitivity during early metastasis formation.  
In another tumor study we found that tumor free survival as well as the tumor 
spectrum of irradiated TRAIL-R-deficient mice was not significantly different from 
wild-type mice, with the majority of observed tumors in both genotypes being 
disseminated lymphomas of B cell origin. Interestingly, in TRAIL-R-deficient mice 
with lymphoma we observed increased dissemination of lymphoma to Peyer’s 
patches, mesenteric lymph nodes, and pancreas, although primary 
lymphomagenesis was not affected (manuscript in preparation). These data 
confirmed our finding of a specific antimetastatic effect of TRAIL-R expression in 
mice. It will be interesting to further analyze whether the anti-metastatic effect of 
endogenous TRAIL signaling via TRAIL-R is particularly important for lymph 
node metastases. This could be facilitated through increased TRAIL expression 
in lymphatic cells or increased sensitization of tumor cells to TRAIL in the 
lymphatic system, for example through cytokines such as γIFN (14).  
Genes that reduce the metastatic propensity of tumor cells without affecting their 
tumorigenicity are defined as metastasis suppressors (15). By these criteria, 
Trail-r is a metastasis suppressor gene. Death of cancer patients is mostly due to 
metastatic spread of the primary tumor. Therefore, it is necessary to improve 
treatment of metastatic disease, for example by increasing expression and 
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function of metastasis suppressors. To date, more than twenty metastasis 
suppressors have been identified, many of which encode for intracellular 
signaling molecules (15) making them difficult to target therapeutically. By 
contrast, TRAIL receptors are expressed on the cell surface, and several TRAIL 
receptor agonists are already in clinical trials (1).  
Implications of the specific role of TRAIL-R in metastasis suppression for 
tumor therapy 
Increased selective pressure against tumor suppressors leads to their loss of 
function during primary tumorigenesis. For example the tumor suppressor p53 is 
mutated in more than 50% of all primary human cancers. Similarly, most 
metastasis suppressors are lost, mutated, or downregulated during the 
metastatic process. If TRAIL-R is also a metastasis suppressor in humans, we 
would predict loss of TRAIL-R-mediated apoptosis signaling in metastatic tumors 
when compared to primary tumors. Indeed, there is evidence for selective 
pressure on inactivating the TRAIL apoptosis pathway specifically in metastases 
by mutation or downregulation of the TRAIL death receptors. This has been 
observed for example in metastases of breast cancer and melanoma (16, 17). 
Furthermore, metastatic cell lines also showed greater TRAIL resistance than 
their counterparts isolated from primary tumors (18). Interestingly, Caspase-8, an 
important downstream signaling component of death-receptors has also been 
identified as a metastasis suppressor (19). The metastasis suppressor function of 
caspase-8 could be also due to its function as a downstream mediator of death 
receptor-mediated apoptosis. 
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Although both Caspase-8 as well as TRAIL-R have been described as 
metastasis suppressors, depending on the context both can also suppress 
primary tumor development. A tumor suppressor function of the TRAIL apoptosis 
pathway could result in TRAIL-resistance of the primary tumor. In contrast, a 
metastasis suppressor role of the TRAIL system could lead to TRAIL-resistance 
at the metastasis stage while the primary tumor might remain sensitive or at least 
sensitizable to TRAIL-receptor-targeting drugs. In the future, it will be important 
to define whether selection for TRAIL-resistance happens by irreversible gene 
mutation of TRAIL death receptors or of other essential signaling components of 
the apoptotic machinery, or by reversible regulation of expression of apoptotic 
modulators. Fortunately, TRAIL resistance is often due to reversible expression 
of TRAIL-R pathway modulators such as upregulation of anti-apoptotic molecules 
such as cFLIP, anti-apoptotic Bcl family proteins, and IAPs, or by downregulation 
of proapoptotic molecules (2). Therefore, TRAIL-sensitivity can be easily 
increased by additional drugs such as the proteasome inhibitor Bortezomib, or 
conventional chemotherapeutics such as cisplatinum or paclitaxel, all of which 
are currently being tested in clinical trials together with TRAIL-receptor targeting 
drugs (1).  
In conclusion, we recently found evidence for a metastasis suppressor function of 
the apoptosis-inducing TRAIL-R in mice, and current evidence suggests a similar 
function in humans. More studies are needed to determine the mechanism(s) 
and conditions by which tumor cells can acquire resistance to TRAIL during 
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metastasis formation. These studies are likely to have major impact for TRAIL-
receptor based cancer therapy. 
Figure legend 
A model for inhibition of metastasis by the apoptosis-inducing TRAIL 
system. Primary skin carcinomas are initially resistant to TRAIL (R), but become 
sensitized (S) by detachment. Activated NK cells expressing TRAIL are the likely 
effector cells that kill detached carcinoma cells via TRAIL-R-mediated apoptosis. 
Detached carcinoma cells not expressing functional TRAIL-R are resistant to 
TRAIL induced apoptosis, which enhances their metastatic ability. The TRAIL 
system could generate selection pressure during metastasis to develop TRAIL 
resistance, either through mutations or downregulation of TRAIL-R or other 
components of the TRAIL apoptosis pathway, which could have a negative 
impact towards TRAIL-based therapy of established metastases.  
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TRAIL-R expression inhibits metastasis formation of skin carcinomas by mediating 
TRAIL-induced apoptosis induced in detached skin carcinoma cells. Cell lines from 
primary skin carcinomas are resistant to TRAIL (RS), but detachment of WT skin carcinoma 
cells leads to sensitization of those cells to TRAIL by detachment (S). Activated NK cells 
express TRAIL, have been shown to mediate anti-tumor effects of TRAIL, and are likely to 
be the effector cells killing detached skin carcinoma cells via TRAIL-R-mediated apoptosis. 
This could potentially lead to selection pressure resulting in TRAIL resistance (RR) in 
detached, early metastasizing cells, either through irreversible mutations or downregulation 
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